Ballentine Partners, LLC Cure Vac N.V. Transaction History
Ballentine Partners, LLC
- $6.57 Billion
- Q2 2025
A detailed history of Ballentine Partners, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Ballentine Partners, LLC holds 37,804 shares of CVAC stock, worth $206,409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,804
Previous 31,573
19.74%
Holding current value
$206,409
Previous $87,000
135.63%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CVAC
# of Institutions
95Shares Held
10.7MCall Options Held
75.1KPut Options Held
86.7K-
Black Rock Inc. New York, NY2.25MShares$12.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.82MShares$9.92 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$8.57 Million10.6% of portfolio
-
Ubs Group Ag843KShares$4.6 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0308KShares$1.68 Million0.08% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $1.02B
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...